BEIJING, March 25, 2011 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) (“Nuokang” or the “Company”), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that its Board of Directors has authorized a share repurchase program, which will allow the Company to buy up to US$5 million worth of its American Depositary Shares.
